Anxiogenic effects in the rat elevated plus-maze of 5-HT2C agonists into ventral but not dorsal hippocampus

Behavioural Pharmacology

Volumn 15, Issue 1, 2004, Pages 37-43

  Alves, S H ^a   Pinheiro, G ^a   Motta, V ^a   Landeira Fernandez, J ^b,c   Cruz, A P M ^a  

^a UNIVERSITY OF BRASILIA   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c ESTÁCIO DE SÁ UNIVERSITY   (Brazil)

Author keywords

5 HT2C receptors; Animal models of anxiety; Dorsal hippocampus; Elevated plus maze; MK 212; Rat; TFMPP; Ventral hippocampus

Indexed keywords

1 (3 TRIFLUOROMETHYLPHENYL)PIPERAZINE; 6 CHLORO 2 (1 PIPERAZINYL)PYRAZINE; SEROTONIN 2C RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; EXPLORATORY BEHAVIOR; HIPPOCAMPUS; LOCOMOTION; MALE; MAZE TEST; MICROINJECTION; NONHUMAN; RAT;

ANIMALS; AROUSAL; BRAIN MAPPING; DOSE-RESPONSE RELATIONSHIP, DRUG; FEAR; HIPPOCAMPUS; MALE; MAZE LEARNING; MICROINJECTIONS; PIPERAZINES; PYRAZINES; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN AGONISTS;

EID: 1242317116     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-200402000-00005     Document Type: Article

References (59)

1. 2C receptors protein in human and rat brain using specific antisera. Neuropharmacology 34:1635-1645.
2. Azmitia EC, Segal M (1978). An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J Comp Neurol 79:641-667.
3. Bannerman DM, Grubb M, Deacon RM, Yee BK, Feldon J, Rawlins JN (2003). Ventral hippocampal lesions affect anxiety but not spatial learning. Behav Brain Res 139:197-213.
4. Belzung C, Le Pape G (1994). Comparison of different behavioral tests situations used in psychopharmacology for measurement of anxiety. Physiol Behav 56:623-628.
5. Benjamin D, Lal H, Meyerson LR (1990). The effects of 5-HT1B characterizing in the mouse elevated plus-maze. Life Sci 47:195-203.
6. Charney DS, Woods SW, Goodman WR, Heninger GR (1987). Serotonin function in anxiety. II. Effects of the serotonin agonist mCPP on panic disorder patients and healthy subjects. Psychopharmacology 92:14-21.
7. Cheeta S, Kenny PJ, File SE (2000). Hippocampal and septal injections of nicotine and 8-OH-DPAT distinguish among different animal tests of anxiety. Prog Neuropsychopharmacol Biol Psychiatry 24:1053-1067.
8. 2C receptor protein in the rat CNS. Neuropharmacology 39:123-132.
9. Cruz AP, Frei F, Graeff FG (1994). Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol Biochem Behav 49:171-176.
10. File SE (1992.) Behavioural detection of anxiolytic actions. In: Elliot JM, Heal DJ, Marsden CA (editors): Experimental Approaches to Anxiety and Depression. London: John Wiley; pp. 25-44.
11. 1A-receptor ligands in dorsal raphe and ventral hippocampus. Pharmacol Biochem Behav 54:123-128.
12. 1A receptor modulation of anxiety in two ethological animal tests. J Neurosci 16:4810-4815.
13. File SE, Kenny PJ, Cheeta S (2000). The role of the dorsal hippocampal serotonergic and cholinergic systems in the modulation of anxiety. Pharmacol Biochem Behav 66:65-72.
14. Fone KC, Shalders K, Fox ZD, Arthur R, Marsden CA (1996). Increased 5-HT2C receptor responsiveness occurs on rearing rats in social isolation. Psychopharmacology 123:346-352.
15. Gatch MB (2003). Discriminative stimulus of m-chlorophenylpiperazine as model of the role of serotonin in anxiety. Life Sci 73:1347-1367.
16. 2C receptors but not by sympathomimetic effects. Neuropharmacology 33:457-465.
17. Graeff FG (2002). On serotonin and experimental anxiety. Psychopharmacology 163:467-476.
18. Graeff FG, Netto CF, Zangrossi H Jr (1998). The elevated T-maze as an experimental model of anxiety. Neurosci Biobehav Rev 23:237-246.
19. Griebel G (1995). 5-Hydroxytryptamine-interaction drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol Ther 65:319-395.
20. (2C) receptors in the rat choroid plexus. Behav Pharmacol 5:642-645.
21. Hajos-Korcsok E, Robinson DD, Yu JC, Fitch CS, Walker E, Merchant KM (2003). Rapid habituation of hippocampal serotonin and norepinephrine release and anxiety-related behaviors, but not plasma corticosterone levels, to repeat footshock stress in rats. Pharmacol Biochem Behav 74:609-616.
22. Handley SL, McBlane JW (1993). 5-HT drugs in animal models of anxiety. Psychopharmacology 112:13-20.
23. Handley SL, Mithani S (1984). Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of 'fear'-motivated behaviour. Naunyn Schmiedebergs Arch Pharmacol 327:1-5.
24. Handley SL, McBlane JW, Critchley MA, Njung'e K (1993). Multiple serotonin mechanisms in animal models of anxiety: environmental, emotional and cognitive factors. Behav Brain Res 58:203-210.
25. Heisler LK, Tecott LH (2000). A paradoxical locomotor response in serotonin 5HT(2C) receptor mutant mice. J Neurosci 20(8):1-5.
26. Hoyer D, Clarke DE, Fozard JR, Hartin PR, Martin GR, Mylercharane EJ, et al. (1994). VII. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 46:157-203.
27. Hutson PH, Sarna, GS, O'Connell MT, Curzon G (1989). Hippocampal 5-HT synthesis and release in vivo is decreased by infusion of 8-OH-DPAT into the nucleus raphé dorsalis. Neurosci Lett 100:276-280.
28. Iversen SC (1984). 5-HT and anxiety. Neuropharmacology 23:1553-1560.
29. 2C receptor mediation of unconditioned escape behaviour in the unstable elevated exposed plus maze. Psychopharmacology 164:214-220.
30. Kahn RS, van Praag HM, Wetzler S, Asnis GM, Barr G (1988). Serotonin and anxiety revisited. Biol Psychiatry 23:189-208.
31. Kennett GA, Curzon G (1988). Evidence that mCPP may have behavioral effects mediated by 5-HT1C receptors. Br J Pharmacol 94:137-147
32. Kennett GA, Whitton P, Shah K, Curzon G (1989). Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists. Eur J Pharmacol 164:445-454.
33. Kjelstrup KG, Tuvnes FA, Steffenach HA, Murison R, Moser EI, Moser MB (2002). Reduced fear expression after lesions of the ventral hippocampus. Proc Natl Acad Sci USA 99:10825-10830.
34. Lister RG (1987). The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92:180-185.
35. Lucki I (1996). Serotonin receptor specificity in anxiety disorders. J Clin Psychiatry 57:5-10.
36. 2C receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 286:913-924.
37. Martin JR, Ballard TM, Higgins GA (2002). Influence of 5-HT2C receptor antagonist, SB-24084, in tests of anxiety. Pharmacol Biochem Behav 71:615-625.
38. McQuade R, Sharp T (1997). Functional mapping of dorsal and median raphe 5-hydroxytryptamine pathways in forebrain of the rat using microdialysis. J Neurochem 69:791-796.
39. Menard J, Treit D (1999). Effects of centrally administered anxiolytic compounds in animal models of anxiety. Neurosci Biobehav Rev 23:591-613.
40. Montgomery KC (1955). The relationship between fear induced by novel stimulation and exploratory behavior. J Comp Physiol Psychol 48:254-260.
41. Moser MB, Moser EI (1998). Functional differentiation in the hippocampus. Hippocampus 8:608-619.
42. Mueller EA, Murphy DL, Sunderland T (1985). Neuroendocrine effects of m-chlorophenylpiperazine, a serotonin agonist, in humans. J Clin Endocrinol Metab 61:1179-1184.
43. Naughton M, Mulrooney JB, Leonard BE (2000). A review of the role of serotonin receptors in psychiatric disorders. Hum Psychopharmacol 15:397-415.
44. Nic Dhonnchadha BA, Bourin M, Hascoet M (2003). Anxiolytic-like effects of 5-HT2 ligands on three mouse models of anxiety. Behav Brain Res 18: 203-214.
45. Nunes-de-Souza R, Canto-deSouza A, Rodgers RJ (2002). Effects of intrahippocampal infusion of WAY-100635 on plus-maze behavior in mice. Brain Res 927:87-96.
46. Paxinos G, Watson C (1986). The Rat Brain in Stereotaxic Coordinates. New York: Academic Press.
47. Pellow S, Chopin P, File SE, Briley M (1985). Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14:149-167.
48. 2C receptors. Brain Res Mol Brain Res 23:163-178.
49. Rodgers RJ (1997). Animal models of 'anxiety': where next? Behav Pharmacol 8:477-496.
50. Rodgers RJ, Cole JC, Cobain MR, Daly P, Doran PJ, Eells JR, Wallis P (1992). Anxiogenic-like effects of fluprazine and eltoprazine in the mouse elevated plus-maze: profile comparisons with 8-OH-DPAT, CGS 12066B, TFMPP and mCPP. Behav Pharmacol 3:621-634.
51. Sena LM, Bueno C, Pobbe RL, Andrade TG, Zangrossi H Jr, Viana MB (2003). The dorsal raphe nucleus exerts opposed control on generalized anxiety and panic-related defensive responses in rats. Behav Brain Res 142:125-133.
52. Setem J, Pinheiro AP, Motta VA, Morato S, Cruz AP (1999). Ethopharmacological analysis of 5-HT ligands on the rat elevated plus-maze. Pharmacol Biochem Behav 62:515-521.
53. (2C) receptors. Neurosci Res 40:97-103.
54. Treit D, Menard J, Royan C (1993). Anxiogenic stimuli in the elevated plus-maze. Pharmacol Biochem Behav 44:463-469.
55. Vertes RP (1991). A PHA-L analysis of ascending projections of the dorsal raphe nucleus in the rat. J Comp Neurol 313:643-648.
56. Voigt JP, Rex A, Sohr R, Fink H (1999). Hippocampal 5-HT and NE release in the transgenic rat TGR(mREN2)27 related to behavior on the elevated plus maze. Eur Neuropsychopharmacol 9:279-285.
57. Wallis CJ, Lal H (1998). A discriminative stimulus produced by 1-(3-chlorophenyl)-piperazine (mCPP) as a putative animal model of anxiety. Prog Neuropsychopharmacol Biol Psychiatry 22:547-565.
58. Whitton P, Curzon G (1990). Anxiogenic-like effect of infusing 1-(3 chlorophenyl) piperazine (mCPP) into the hippocampus. Psychopharmacology 100: 138-140.
59. Wright IK, Upton N, Marsden CA (1992). Effect of established and putative anxiolytics on extracellular 5-HT and 5-HIAA in ventral hippocampus of rats during behaviour on the elevated X-maze. Psychopharmacology 109: 338-346.